“…It soon turned out that miRNAs can be differentially expressed in various tumor types, either benign or malignant [58], and their effect on tumor progression might be connected with the modulation of development of new blood vessels, both via promoting angiogenesis (angiomirs) or through its inhibition (anti-angiomirs) [59]. Anti-angiomirs, including miR-15a, miR-16, miR-125b, miR-199a, or miR-200b target proangiogenic VEGF and their expression could be decreased in different tumor types including lymphomas, multiple myelomas, lung, colorectal, hepatocellular, ovarian, oral, and breast cancer [60][61][62]. VEGF may be not only inhibited by miRNAs, but it can also be activated by them.…”